The board comprises two Executive Directors and three Non-Executive Directors.
Chris SpencerNon-Executive Chairman
Chris has nearly 40 years’ experience in software, healthcare, and legal matters. He joined EMIS Group plc in 1999 holding senior roles including Chief Administrative Officer and, from 2013, Chief Executive Officer. Currently he serves on a number of digital health related private company boards and is a Digital Health Venture Partner for GM&C Life Sciences Fund at Catapult Ventures Group.
Chris is a solicitor (non-practising). Formerly an Associate of the Chartered Institute of Patent Agents and member of the Law Society of England and Wales and Fellow of the Chartered Management Institute he remains a member of the Society for Computers and Law. He holds an LLB (Hons) and qualified as a solicitor (with distinction).
Hugo StephensonNon-executive Director
Hugo has founded several healthcare and biotech services businesses including DrugDev (acquired by IQVIA) MediGuard (owned by IQVIA), Health Research Solutions (acquired by Quintiles, now IQVIA), and MedSeed (acquired by eHealthcare Asia).
Hugo served as full-time Executive Chairman, Product Lead and co-founder at DrugDev from 2012-2017. Previously, Hugo served as Vice President at Quintiles (now IQVIA) from 2002 to 2011.
Ibs MahmoodChief Executive Officer
Ibs has a broad background in healthcare, technology and finance having read Medicine at Oxford, worked as a Healthcare Strategy Consultant at Accenture, Healthcare Investment Banker at Nomura, Lifesciences Equity Research Analyst at Investec and Corporate Venture Capitalist at Shire Pharmaceuticals.
Most recently, Ibs was President and CEO of DrugDev - a leading clinical trial technology company. Between 2011 and 2018 Ibs oversaw the growth of the company from just three people to approximately a thousand with the concomitant growth in the order book of sold business from zero to several hundred million dollars. He also led funding rounds of well over $50m and the sale of the business to IQVIA - the largest clinical research organisation in the world where he worked until late 2018 running their Global Clinical technology business. He also worked as an Entrepreneur-in-Residence for Oxford University’s affiliated $1bn technology transfer fund.
Seb JantetChief Financial Officer
Seb has over 25 years of experience in finance, both in the public and private markets. Most recently he was chief financial officer of DrugDev Inc, which he joined in 2013 and was part of the team that executed a buy and build strategy in the clinical trials technology market, ultimately culminating in a successful exit to IQIVIA in 2017.
Prior to that Seb spent 22 years working in the City. During this period he spent 11 years working at Investec where he was a top ranked healthcare analyst and headed up the healthcare equity research team. Prior to that he worked for KPMG where he spent 4 years working in corporate finance.
He is a qualified accountant, a member of the Institute of Chartered Accountants of England and Wales and has a BA in French and Politics from the University of East Anglia. He is also a non-executive director of Elizabeth Finn Homes Limited.
Jane SilberNon-executive Director
Jane is Executive Chair of Diffblue Ltd and a non-executive director of The Sensible Code Company Limited. She also serves as an advisor for tech start-ups.
Previously she was CEO of Canonical for 7 years, which followed a 7 year period as COO of Canonical. With experience in the US, Japan and the UK, she has spent her entire career in software engineering and IT management, starting as a software developer and rising through various leadership roles. She holds a BS from Haverford College, an MS from Vanderbilt University, and an MBA from Oxford University.